Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Combination therapies show promise for advanced head and neck cancer
This meta-analysis evaluated combination therapies involving targeted agents or immunotherapy with chemotherapy for patients with recurrent …
Combining immunotherapy or targeted drugs with chemotherapy may help patients with advanced head and neck cancer live longer without the dis…
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
New cancer treatment may cause rare brain inflammation in patients
This case report and literature review describes a patient with advanced esophageal squamous cell carcinoma who developed autoimmune GFAP as…
A new type of immunotherapy for esophageal cancer can trigger a rare brain condition, requiring doctors to watch for early signs of neurolog…
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma
Immune therapy shows promise for esophageal squamous cell carcinoma
This meta-analysis of randomized controlled trials involving 1070 patients found that neoadjuvant chemoimmunotherapy (NIC) significantly imp…
Adding immune checkpoint inhibitors to chemotherapy before surgery significantly improves tumor response rates in patients with esophageal c…
Hyperspectral imaging shows strong diagnostic performance for oral cancer detection in scoping review
Hyperspectral imaging shows promise for detecting oral cancer
This scoping review of 15 studies found that hyperspectral imaging (HSI) demonstrates strong diagnostic performance for detecting and charac…
A new review finds hyperspectral imaging can spot oral cancer with high accuracy, offering a non-contact alternative for margin assessment.
Early recognition of femoral metastasis in HNSCC is essential to facilitate timely palliative intervention
New data reveals management of head and neck cancer spread
This systematic review characterizes clinical features and management outcomes for patients with head and neck squamous cell carcinoma (HNSC…
Identifying how head and neck cancer spreads to the femur can help doctors provide better care and improve quality of life for patients.
Pretreatment CPS and HPV status correlate with pathological response in neoadjuvant immunotherapy for LAHNSCC
Certain markers may predict how well immunotherapy treats head cancer
This meta-analysis of 26 studies involving 980 patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) found that hig…
New data suggests that specific biological markers can help doctors predict how well a patient's tumor will respond to immunotherapy.
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
Oral diseases stem from disrupted host-microbiome-immune balance, narrative review argues
New research explores how oral bacteria drive gum disease
This narrative review argues that periodontitis, dental caries, and oral squamous cell carcinoma should be understood as disorders of host-m…
Oral health depends on a delicate balance between your immune system, tissue barriers, and the trillions of microbes living in your mouth.
HOX gene dysregulation influences cellular processes but currently lacks utility as reliable HNSCC biomarkers
HOX genes play complex roles in head and neck cancer
This mini-review examines the role of HOX genes in head and neck squamous cell carcinoma (HNSCC). The authors conclude that while these gene…
New research highlights how HOX genes drive tumor growth and survival in head and neck cancers, though their use as clinical tools is still …